NCT00896298View on ClinicalTrials.gov

Trial of Leptin Replacement Therapy in Patients With Lipodystrophy

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
HypoleptinemiaGeneralized LipodystrophyPartial LipodystrophyInsulin Resistance
Interventions
DRUG

Leptin

Leptin injected subcutaneously twice a day, to be administered at 100% of the estimated replacement dose during the first month, which is a dosage of 0.03mg/kg for female children, 0.04mg/kg for adult females, and0.02 mg/kg for all males, and then at 200% subsequently, or placebo.

DRUG

Placebo

Sugar pill

Trial Locations (1)

75390

UT Southwestern Medical Center, Dallas

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER

NCT00896298 - Trial of Leptin Replacement Therapy in Patients With Lipodystrophy | Biotech Hunter | Biotech Hunter